Ontology type: schema:ScholarlyArticle Open Access: True
2008-06-27
AUTHORS ABSTRACTBetween 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy. More... »
PAGES24-29
http://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z
DOIhttp://dx.doi.org/10.1007/s12185-008-0118-z
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1010032558
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/18581200
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Cardiorespiratory Medicine and Haematology",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Blood Transfusion",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Education, Medical, Continuing",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Iron Chelating Agents",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Iron Overload",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Myelodysplastic Syndromes",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Practice Guidelines as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Societies, Medical",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Transfusion Reaction",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany",
"id": "http://www.grid.ac/institutes/grid.411327.2",
"name": [
"Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany"
],
"type": "Organization"
},
"familyName": "Gattermann",
"givenName": "Norbert",
"id": "sg:person.01273447501.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34"
],
"type": "Person"
}
],
"datePublished": "2008-06-27",
"datePublishedReg": "2008-06-27",
"description": "Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy.",
"genre": "article",
"id": "sg:pub.10.1007/s12185-008-0118-z",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1076985",
"issn": [
"0925-5710",
"1865-3774"
],
"name": "International Journal of Hematology",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "88"
}
],
"keywords": [
"iron chelation therapy",
"transfusional iron overload",
"myelodysplastic syndrome",
"iron overload",
"chelation therapy",
"red blood cell transfusion",
"lower-risk myelodysplastic syndromes",
"National Comprehensive Cancer Network",
"blood cell transfusion",
"Comprehensive Cancer Network",
"MDS Foundation",
"cell transfusion",
"symptomatic anemia",
"guideline group",
"consensus statement",
"Cancer Network",
"healthcare professionals",
"therapy",
"patients",
"overview of guidelines",
"Italian Society",
"transfusion",
"ongoing management",
"syndrome",
"overload",
"guidelines",
"group",
"anemia",
"hematology",
"management",
"treatment",
"professionals",
"recommendations",
"strategies",
"number",
"overview",
"statements",
"region",
"society",
"approach",
"world",
"foundation",
"network"
],
"name": "Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload",
"pagination": "24-29",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1010032558"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s12185-008-0118-z"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"18581200"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s12185-008-0118-z",
"https://app.dimensions.ai/details/publication/pub.1010032558"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T16:57",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_455.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s12185-008-0118-z"
}
]
Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12185-008-0118-z'
This table displays all metadata directly associated to this object as RDF triples.
140 TRIPLES
20 PREDICATES
77 URIs
69 LITERALS
16 BLANK NODES
Subject | Predicate | Object | |
---|---|---|---|
1 | sg:pub.10.1007/s12185-008-0118-z | schema:about | N01dd8de5bd184d1b99e06aa3e7da51b5 |
2 | ″ | ″ | N57823c22c29f486096b18595ece762f1 |
3 | ″ | ″ | N5901808a25d24c6ab1a41a00e14a962b |
4 | ″ | ″ | N5c3994a37dad4621971f15dd02683d10 |
5 | ″ | ″ | N9bade7d5af1e4c78a8048d9f382f90d9 |
6 | ″ | ″ | Na7fa702d286b466fa1cb9b0d595fb0c1 |
7 | ″ | ″ | Nb90aa49d6f394e8883f942962b4e792a |
8 | ″ | ″ | Ncdf8b2dfbc4148ab83ee1ceb3722934d |
9 | ″ | ″ | Nd6bd4e68bcea4b6d9fae79ca193dfc3b |
10 | ″ | ″ | anzsrc-for:11 |
11 | ″ | ″ | anzsrc-for:1102 |
12 | ″ | schema:author | N521dc8315d0a4c4089e67da7f4af0423 |
13 | ″ | schema:datePublished | 2008-06-27 |
14 | ″ | schema:datePublishedReg | 2008-06-27 |
15 | ″ | schema:description | Between 2002 and 2008, a number of consensus statements and guidelines were developed by various groups around the world to educate healthcare professionals on the treatment of myelodysplastic syndromes (MDS), including the management of transfusional iron overload with iron chelation therapy. Guidelines have been developed by The Italian Society of Hematology, The UK MDS Guidelines Group, The Nagasaki Group, The National Comprehensive Cancer Network, and The MDS Foundation. These guidelines show that the approaches to managing iron overload in patients with MDS are region specific, differing in their recommendations for when iron chelation therapy should be initiated and strategies for the ongoing management of iron overload. The guidelines all agree that red blood cell transfusions are clinically beneficial to treat the symptomatic anemia in MDS, and that patients with low-risk MDS receiving transfusions are the most likely to benefit from iron chelation therapy. |
16 | ″ | schema:genre | article |
17 | ″ | schema:isAccessibleForFree | true |
18 | ″ | schema:isPartOf | N492cb10fbdfc44aa9fe9601dcacf434a |
19 | ″ | ″ | Nc984a7e6037d4a84b491a2294df5de5b |
20 | ″ | ″ | sg:journal.1076985 |
21 | ″ | schema:keywords | Cancer Network |
22 | ″ | ″ | Comprehensive Cancer Network |
23 | ″ | ″ | Italian Society |
24 | ″ | ″ | MDS Foundation |
25 | ″ | ″ | National Comprehensive Cancer Network |
26 | ″ | ″ | anemia |
27 | ″ | ″ | approach |
28 | ″ | ″ | blood cell transfusion |
29 | ″ | ″ | cell transfusion |
30 | ″ | ″ | chelation therapy |
31 | ″ | ″ | consensus statement |
32 | ″ | ″ | foundation |
33 | ″ | ″ | group |
34 | ″ | ″ | guideline group |
35 | ″ | ″ | guidelines |
36 | ″ | ″ | healthcare professionals |
37 | ″ | ″ | hematology |
38 | ″ | ″ | iron chelation therapy |
39 | ″ | ″ | iron overload |
40 | ″ | ″ | lower-risk myelodysplastic syndromes |
41 | ″ | ″ | management |
42 | ″ | ″ | myelodysplastic syndrome |
43 | ″ | ″ | network |
44 | ″ | ″ | number |
45 | ″ | ″ | ongoing management |
46 | ″ | ″ | overload |
47 | ″ | ″ | overview |
48 | ″ | ″ | overview of guidelines |
49 | ″ | ″ | patients |
50 | ″ | ″ | professionals |
51 | ″ | ″ | recommendations |
52 | ″ | ″ | red blood cell transfusion |
53 | ″ | ″ | region |
54 | ″ | ″ | society |
55 | ″ | ″ | statements |
56 | ″ | ″ | strategies |
57 | ″ | ″ | symptomatic anemia |
58 | ″ | ″ | syndrome |
59 | ″ | ″ | therapy |
60 | ″ | ″ | transfusion |
61 | ″ | ″ | transfusional iron overload |
62 | ″ | ″ | treatment |
63 | ″ | ″ | world |
64 | ″ | schema:name | Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload |
65 | ″ | schema:pagination | 24-29 |
66 | ″ | schema:productId | N224d225c53e24b2987f43abaf8445588 |
67 | ″ | ″ | N6aab895b72fb4fd1896a8ad92efe651f |
68 | ″ | ″ | Naaa691da948949b9a6c04ed8655bc50f |
69 | ″ | schema:sameAs | https://app.dimensions.ai/details/publication/pub.1010032558 |
70 | ″ | ″ | https://doi.org/10.1007/s12185-008-0118-z |
71 | ″ | schema:sdDatePublished | 2022-08-04T16:57 |
72 | ″ | schema:sdLicense | https://scigraph.springernature.com/explorer/license/ |
73 | ″ | schema:sdPublisher | Nef56c1e558d649f2bab412ab945e641f |
74 | ″ | schema:url | https://doi.org/10.1007/s12185-008-0118-z |
75 | ″ | sgo:license | sg:explorer/license/ |
76 | ″ | sgo:sdDataset | articles |
77 | ″ | rdf:type | schema:ScholarlyArticle |
78 | N01dd8de5bd184d1b99e06aa3e7da51b5 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
79 | ″ | schema:name | Iron Chelating Agents |
80 | ″ | rdf:type | schema:DefinedTerm |
81 | N224d225c53e24b2987f43abaf8445588 | schema:name | doi |
82 | ″ | schema:value | 10.1007/s12185-008-0118-z |
83 | ″ | rdf:type | schema:PropertyValue |
84 | N492cb10fbdfc44aa9fe9601dcacf434a | schema:issueNumber | 1 |
85 | ″ | rdf:type | schema:PublicationIssue |
86 | N521dc8315d0a4c4089e67da7f4af0423 | rdf:first | sg:person.01273447501.34 |
87 | ″ | rdf:rest | rdf:nil |
88 | N57823c22c29f486096b18595ece762f1 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
89 | ″ | schema:name | Societies, Medical |
90 | ″ | rdf:type | schema:DefinedTerm |
91 | N5901808a25d24c6ab1a41a00e14a962b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
92 | ″ | schema:name | Blood Transfusion |
93 | ″ | rdf:type | schema:DefinedTerm |
94 | N5c3994a37dad4621971f15dd02683d10 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
95 | ″ | schema:name | Myelodysplastic Syndromes |
96 | ″ | rdf:type | schema:DefinedTerm |
97 | N6aab895b72fb4fd1896a8ad92efe651f | schema:name | pubmed_id |
98 | ″ | schema:value | 18581200 |
99 | ″ | rdf:type | schema:PropertyValue |
100 | N9bade7d5af1e4c78a8048d9f382f90d9 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
101 | ″ | schema:name | Humans |
102 | ″ | rdf:type | schema:DefinedTerm |
103 | Na7fa702d286b466fa1cb9b0d595fb0c1 | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
104 | ″ | schema:name | Practice Guidelines as Topic |
105 | ″ | rdf:type | schema:DefinedTerm |
106 | Naaa691da948949b9a6c04ed8655bc50f | schema:name | dimensions_id |
107 | ″ | schema:value | pub.1010032558 |
108 | ″ | rdf:type | schema:PropertyValue |
109 | Nb90aa49d6f394e8883f942962b4e792a | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
110 | ″ | schema:name | Iron Overload |
111 | ″ | rdf:type | schema:DefinedTerm |
112 | Nc984a7e6037d4a84b491a2294df5de5b | schema:volumeNumber | 88 |
113 | ″ | rdf:type | schema:PublicationVolume |
114 | Ncdf8b2dfbc4148ab83ee1ceb3722934d | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
115 | ″ | schema:name | Transfusion Reaction |
116 | ″ | rdf:type | schema:DefinedTerm |
117 | Nd6bd4e68bcea4b6d9fae79ca193dfc3b | schema:inDefinedTermSet | https://www.nlm.nih.gov/mesh/ |
118 | ″ | schema:name | Education, Medical, Continuing |
119 | ″ | rdf:type | schema:DefinedTerm |
120 | Nef56c1e558d649f2bab412ab945e641f | schema:name | Springer Nature - SN SciGraph project |
121 | ″ | rdf:type | schema:Organization |
122 | anzsrc-for:11 | schema:inDefinedTermSet | anzsrc-for: |
123 | ″ | schema:name | Medical and Health Sciences |
124 | ″ | rdf:type | schema:DefinedTerm |
125 | anzsrc-for:1102 | schema:inDefinedTermSet | anzsrc-for: |
126 | ″ | schema:name | Cardiorespiratory Medicine and Haematology |
127 | ″ | rdf:type | schema:DefinedTerm |
128 | sg:journal.1076985 | schema:issn | 0925-5710 |
129 | ″ | ″ | 1865-3774 |
130 | ″ | schema:name | International Journal of Hematology |
131 | ″ | schema:publisher | Springer Nature |
132 | ″ | rdf:type | schema:Periodical |
133 | sg:person.01273447501.34 | schema:affiliation | grid-institutes:grid.411327.2 |
134 | ″ | schema:familyName | Gattermann |
135 | ″ | schema:givenName | Norbert |
136 | ″ | schema:sameAs | https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01273447501.34 |
137 | ″ | rdf:type | schema:Person |
138 | grid-institutes:grid.411327.2 | schema:alternateName | Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany |
139 | ″ | schema:name | Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University, Moorenstr. 5, 40225, Dusseldorf, Germany |
140 | ″ | rdf:type | schema:Organization |